GLP-3RT is one of the most-discussed research peptides in modern incretin biology. The reason is simple: it is a triple-receptor agonist. Where earlier-generation peptides in this space act on one or two receptors, GLP-3RT is studied as a single molecule that engages three at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor.
If you have been following peptide-research conversations on Reddit, X, or in lab group chats, you have almost certainly seen GLP-3RT come up under another name: retatrutide. The two terms point to the same research compound. The “RT” in GLP-3RT is the same RT in retatrutide.
This article is a plain-English, research-only guide to what GLP-3RT is, how it differs from related peptides like tirzepatide and semaglutide, and why labs studying incretin biology are paying close attention to it.
What Is GLP-3RT?
GLP-3RT is a synthetic 39-amino-acid peptide engineered as a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). The molecule is the same compound discussed in scientific literature as retatrutide.
From a research standpoint, GLP-3RT is interesting because it allows simultaneous study of three receptor systems in a single experimental setup. Most prior incretin-family peptides act on one or two of these receptors:
- Semaglutide (single agonist): GLP-1 receptor only
- Tirzepatide (dual agonist): GLP-1 + GIP receptors
- Retatrutide / GLP-3RT (triple agonist): GLP-1 + GIP + glucagon receptors
That third receptor — glucagon — is the key reason researchers describe GLP-3RT as a “next-generation” tool in incretin pharmacology research. ARG Peptides supplies GLP-3RT in three lyophilized research sizes for qualified researchers, including a 48mg flagship size.
Why The Triple-Agonist Approach Matters
Single and dual receptor agonists already produced significant research interest because of the layered metabolic and signaling pathways they engage. Adding the glucagon receptor to that picture is what gives GLP-3RT its distinct profile in modern research.
Glucagon receptor signaling is involved in different biological pathways than GLP-1 or GIP signaling. By acting on all three at once, GLP-3RT lets a single molecule probe interactions across receptor systems that previously required separate compounds, separate studies, and separate experimental controls.
This is why the broader incretin research community frequently describes GLP-3RT as the “third generation” beyond tirzepatide. Tirzepatide expanded the field from one receptor (GLP-1) to two (GLP-1 + GIP). Retatrutide / GLP-3RT pushes it to three.
GLP-3RT vs Tirzepatide vs Semaglutide
To put GLP-3RT in context with the rest of the incretin-family research peptide lineup:
| Compound | Receptor Profile | Generation |
|---|---|---|
| Semaglutide (GLP-1SG) | GLP-1 only | Single agonist |
| Tirzepatide (GLP-2TZ) | GLP-1 + GIP | Dual agonist |
| Retatrutide (GLP-3RT) | GLP-1 + GIP + Glucagon | Triple agonist |
For deeper comparison context, see our Tirzepatide vs Retatrutide research comparison and Semaglutide vs Tirzepatide overview.
Structural Notes
GLP-3RT is a synthetic peptide built around a 39-amino-acid backbone with engineered modifications that extend its circulating half-life and tune its receptor affinity profile. The molecule is supplied in lyophilized (freeze-dried) form for laboratory research, the standard format for stable peptide storage and reconstitution by qualified researchers.
Like other modern incretin-family research peptides, GLP-3RT is studied at the protein and receptor level, not in dietary supplement contexts. It is a research reference compound.
Where GLP-3RT Fits In Modern Research
The triple-agonist mechanism makes GLP-3RT relevant for any laboratory studying:
- Incretin receptor pharmacology — comparing single, dual, and triple receptor engagement in a controlled experimental design
- Glucagon receptor research — studying glucagon signaling alongside GLP-1 and GIP in a single peptide tool
- Receptor selectivity and crosstalk — investigating how different receptor subtypes interact when engaged simultaneously
- Comparative incretin studies — benchmarking newer triple agonists against established dual-agonist references like tirzepatide
This is why GLP-3RT has become one of the most-requested research peptides in 2025 and 2026 catalogs.
Key Takeaways
- GLP-3RT and retatrutide are the same research compound
- It is a triple-receptor agonist acting on GLP-1, GIP, and glucagon receptors
- It is the next-generation step beyond tirzepatide (which is dual: GLP-1 + GIP) and semaglutide (which is single: GLP-1 only)
- Supplied as a lyophilized synthetic peptide for laboratory research use only
For the full ARG Peptides incretin-family research catalog, browse the research peptide shop. For background on peptide research generally, see our comprehensive peptide guide for researchers.
FOR LABORATORY RESEARCH USE ONLY: ARG Peptides products are research chemicals sold strictly for in vitro and laboratory research. They are not intended for human or animal consumption, and no therapeutic or medical claims are made or implied.
